Verastem Inc Dossier
Qualitative Analysis
Business overview
Verastem, Inc. (operating as Verastem Oncology) is a commercial-stage biopharmaceutical company dedicated to developing and commercializing novel small molecule drugs that target critical signaling pathways driving cancer cell survival and tumor growth. The company's primary focus is on RAS/MAPK pathway-driven cancers. Its lead commercial product is the AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets), which is the first FDA-approved treatment specifically indicated for adults with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. Verastem's pipeline also includes VS-7375, a potential best-in-class oral selective KRAS G12D dual ON/OFF inhibitor currently in Phase 1/2 clinical development for pancreatic, non-small cell lung, and colorectal cancers.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Maximizing the commercial launch and market adoption of AVMAPKI FAKZYNJA CO-PACK, the first FDA-approved treatment specifically for adults with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC).
Expected impact: Establish a sustainable, self-funding commercial foundation to fuel long-term growth.
Accelerating the clinical development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, by initiating Phase 2 registration-directed clinical trials (TARGET-D 201, TARGET-D 202, and TARGET-D 203) in pancreatic, lung, and colorectal cancers.
Expected impact: Establish a best-in-class therapeutic profile in multiple high-value solid tumor indications.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Verastem with an exclusive option to obtain a license for up to three oncology discovery programs targeting RAS/MAPK pathway-driven cancers, including the lead program VS-7375.
Terms: Verastem exercised its license for VS-7375 in January 2025, paying an option exercise fee to GenFleet. Verastem holds development and commercialization rights outside of GenFleet's markets.